A promising new treatment, VES001, for frontotemporal dementia (FTD) has successfully cleared its first major safety hurdle in early-stage clinical trials.

Aperture will advance APRTX-001 as a potential treatment for ALS and frontotemporal dementia, with possible expansion for use ...

A new pill for treating dementia is delivering promising "topline" results in early-stage clinical trials, according to a ...

Late-breaking oral presentation by a leading global authority in Dementia with Lewy bodies (DLB) to highlight updated data from Phase 2b study on ...

Lucid Capital analyst Elemer Piros initiated coverage of Passage Bio (PASG) with a Buy rating and $68 price target Passage Bio, which has ...

Actress Rumer Willis provided a candid update about her father Bruce Willis’s ongoing battle with frontotemporal dementia ...

Bruce Willis' wife, Emma Heming, had a simple response to critics who bashed her for moving her dementia-stricken husband out ...

Rumer Willis—the eldest daughter of exes Bruce Willis and Demi Moore—detailed her latest visits with her dad amid his ongoing ...

Rumer Willis says it’s not so simple to answer how her dad Bruce Willis is doing. Rumer, 37, who is the eldest daughter of ...

Aperture Therapeutics Inc. has nominated APRTX-001 as a development candidate, with the program now advancing through IND-enabling studies. APRTX-001 is a CD33-targeting antisense oligonucleotide (ASO ...

This first-in-class ASO replicates the protective effects of naturally occurring CD33 loss-of-function variants, which are associated with increased resilience to neurodegenerative disease, reduced ...